My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 397

    1.

    Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.

    May LD, Lefkowitch JH, Kram MT, Rubin DE.

    Ann Intern Med. 2002 Mar 19;136(6):449-52.PMID: 11900497 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.

    [No authors listed]

    Ann Intern Med. 2002 Mar 19;136(6):I65. No abstract available. Erratum in: Ann Intern Med 2002 May 7;136(9):711. PMID: 11900516 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Second-generation thiazolidinediones and hepatotoxicity.

    Marcy TR, Britton ML, Blevins SM.

    Ann Pharmacother. 2004 Sep;38(9):1419-23. Epub 2004 Jul 20.PMID: 15266041 [PubMed - indexed for MEDLINE]Related articles

    4.

    Hepatocellular injury in a patient receiving rosiglitazone. A case report.

    Al-Salman J, Arjomand H, Kemp DG, Mittal M.

    Ann Intern Med. 2000 Jan 18;132(2):121-4. Erratum in: Ann Intern Med 2000 Aug 1;133(3):237. PMID: 10644273 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Hepatotoxicity with thiazolidinediones: is it a class effect?

    Scheen AJ.

    Drug Saf. 2001;24(12):873-88. Review.PMID: 11735645 [PubMed - indexed for MEDLINE]Related articles

    6.

    Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

    Lebovitz HE, Kreider M, Freed MI.

    Diabetes Care. 2002 May;25(5):815-21.PMID: 11978674 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.

    Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B.

    Dig Dis Sci. 2002 Jul;47(7):1632-7.PMID: 12141828 [PubMed - indexed for MEDLINE]Related articles

    8.

    Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

    Tolman KG, Freston JW, Kupfer S, Perez A.

    Drug Saf. 2009;32(9):787-800. doi: 10.2165/11316510-000000000-00000.PMID: 19670918 [PubMed - indexed for MEDLINE]Related articles

    9.

    Hepatic failure in a patient taking rosiglitazone.

    Forman LM, Simmons DA, Diamond RH.

    Ann Intern Med. 2000 Jan 18;132(2):118-21.PMID: 10644272 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Severe but reversible cholestatic liver injury after pioglitazone therapy.

    Pinto AG, Cummings OW, Chalasani N.

    Ann Intern Med. 2002 Nov 19;137(10):857. No abstract available. PMID: 12435231 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Troglitazone-induced hepatic failure leading to liver transplantation. A case report.

    Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM.

    Ann Intern Med. 1998 Jul 1;129(1):38-41.PMID: 9652998 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Rosiglitazone-induced granulomatous hepatitis.

    Dhawan M, Agrawal R, Ravi J, Gulati S, Silverman J, Nathan G, Raab S, Brodmerkel G Jr.

    J Clin Gastroenterol. 2002 May-Jun;34(5):582-4.PMID: 11960075 [PubMed - indexed for MEDLINE]Related articles

    13.

    Severe cholestatic hepatitis caused by azathioprine.

    Eisenbach C, Goeggelmann C, Flechtenmacher C, Stremmel W, Encke J.

    Immunopharmacol Immunotoxicol. 2005;27(1):77-83.PMID: 15803861 [PubMed - indexed for MEDLINE]Related articles

    14.

    Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.

    Nagasaka S, Abe T, Kawakami A, Kusaka I, Nakamura T, Ishikawa S, Saito T, Ishibashi S.

    Diabet Med. 2002 Apr;19(4):347-8. No abstract available. PMID: 11943013 [PubMed - indexed for MEDLINE]Related articles

    15.

    A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

    Clin Ther. 2003 Apr;25(4):1074-95.PMID: 12809958 [PubMed - indexed for MEDLINE]Related articles

    16.

    Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast.

    Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ.

    Ann Intern Med. 2000 Dec 19;133(12):964-8.PMID: 11119397 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Thiazolidinedione hepatotoxicity: a class effect?

    Tolman KG.

    Int J Clin Pract Suppl. 2000 Oct;(113):29-34. Review.PMID: 11965828 [PubMed - indexed for MEDLINE]Related articles

    18.

    Lessons from the glitazones: a story of drug development.

    Gale EA.

    Lancet. 2001 Jun 9;357(9271):1870-5. Review.PMID: 11410214 [PubMed - indexed for MEDLINE]Related articles

    19.

    A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K.

    N Engl J Med. 2006 Nov 30;355(22):2297-307.PMID: 17135584 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Hepatocellular injury in a patient receiving pioglitazone.

    Maeda K.

    Ann Intern Med. 2001 Aug 21;135(4):306. No abstract available. PMID: 11511159 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity